Outcomes of post-prostatectomy radiotherapy at a Regional Cancer Centre

Luke Nicholls, MBBS,1,2 Amber Winter, MBBS,1 Ashley Harwood, BAppSci,1 Ashley Plank, PhD,3 Preeti Bagga, FRANZCR,1 Winnie Wong, FRANZCR,1 & Eric Khoo, FRANZCR1,2

1Radiation Oncology Centres, St Andrews Cancer Care, Toowoomba, Queensland, Australia
2School of Medicine, University of Queensland, St Lucia, Brisbane, Queensland, Australia
3Oncology Research Australia, St Andrews Cancer Care, Toowoomba, Queensland, Australia

Keywords
Prostate cancer, prostatectomy, radiation therapy, regional cancer centre.

Correspondence
Luke Nicholls, Radiation Oncology Centres, St Andrews Cancer Care, Toowoomba Queensland 4350, Australia.
Tel: +61 7 4614 5800;
Fax: +61 7 4614 5801;
E-mail: luke1.nicholls@gmail.com

Funding Information
No funding information provided.

Received: 3 March 2017; Revised: 1 July 2017; Accepted: 8 July 2017

J Med Radiat Sci 64 (2017) 259–265
doi: 10.1002/jmrs.240

Abstract

Introduction: To investigate the efficacy and toxicity of radiation therapy (RT) after radical prostatectomy (RP) for prostate cancer at Radiation Oncology Centres, Toowoomba. Methods: The electronic medical records of 130 consecutive patients with histologically proven prostate adenocarcinoma who underwent post-prostatectomy RT between January 2008 and December 2014 were analysed. Primary endpoint was Biochemical Recurrence (BCR) after RT. BCR was defined by PSA > 0.2 ng/mL and BCR endpoints were analysed using Kaplan–Meier methods. The impact of RT technique and the rates of acute and late toxicities are also reported. Toxicities were graded according to Radiation Therapy Oncology Group (RTOG) criteria. Results: Median follow-up time after RT (regardless of technique) was 28 months. BCR occurred in 32 of the 126 patients (25%) whose prostate specific antigen (PSA) levels have been monitored post-RT. At 24 and 36 months, 85% and 75% of patients were BCR-free, respectively. Patients with a pre-RT PSA above 0.2 ng/mL had a higher probability of recurrence than patients with values below 0.2 ng/mL (P = 0.03). RT technique, pelvic nodal irradiation, androgen deprivation therapy, T staging or surgical margin did not significantly impact BCR results. No patient experienced acute toxicities greater than grade 2. Grade 1 or 2 late gastrointestinal (GI) toxicity occurred in 11% and 1 patient experienced a grade 3 event. 12% of patients developed grade 1 or 2 late genitourinary (GU) toxicity, with evidence of grade 3 severity in only 1 patient. Evidence of a trend in reduction in late GI toxicity with the use of intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) was apparent but not with late GU toxicity. Conclusion: At our regional centre, early RT (PSA < 0.2 ng/mL) was associated with significant improvement in BCR-free survival. Rates of toxicity mirror those of landmark trials which suggest no detriment for our regional prostate cancer patients. The use of IMRT/VMAT techniques was associated with a trend towards reduced rates of GI toxicity.

Introduction

In the last 10 years, there has been dramatic changes in the pattern of care for men with localised high risk prostate cancer (HRPC). Historically, these men were often managed with androgen deprivation therapy (ADT), external beam radiation therapy (EBRT), or both, while the use of surgery was uncommon due to high risk of occult metastatic disease, concerns of surgical related morbidities and infrequent use of ADT.1 Recently, however, the use of radical prostatectomy (RP) in appropriately selected patients has emerged as a viable treatment option due to improved surgical skill, reduction in complication rates1 and the increasing use of robotic surgery.2 Perhaps there is also unfounded concern from the surgical discipline regarding the toxicity of
radiation therapy (RT).\textsuperscript{3} Whilst surgical technique is improving, so too is the delivery of EBRT. Use of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) has markedly reduced the rates of severe gastrointestinal (GI) or genitourinary (GU) toxicity whilst simultaneously allowing dose escalation to the planning target volume (PTV).\textsuperscript{4}

Unfortunately, 10–25\% of patients experience recurrence after RP.\textsuperscript{5} Patients with adverse risk factors such as high level of prostate-specific antigen (PSA), stage pT3, positive surgical margins (R1), and Gleason score \( \geq 8 \) may have up to a 75\% chance of biochemical recurrence (BCR) at 10 years, necessitating the use of post-RP RT. Thus, the increasing utilisation of RP will possibly lead to increased rates of post-RP RT and increased reliance on regional cancer centres (RCC). The reporting of outcomes from RCC is essential in an era of decentralised medical delivery as the community’s expectation is that the quality of treatment received in RCC is equivalent to metropolitan centres.

Toowoomba is classified as an Inner Regional centre and has a population of approximately 150,000.\textsuperscript{6} Radiation Oncology Centres (ROC), Toowoomba provides the sole RT service to a large portion of the Darling Downs and South West Queensland regions. This study investigates the efficacy and toxicity of RT after RP for prostate cancer at our RCC.

\section*{Method}

This study is predominantly a quality assurance audit and thus a request for waiver of Human Research Ethics Committee review was approved by Oncology Research Australia. The electronic medical records of 130 consecutive patients with histologically proven prostate adenocarcinoma who underwent post-RP RT between January 2008 and December 2014 were retrospectively analysed. All patients completed the prescribed course of RT and no patients were excluded. All were assessed for Gleason score, TNM stage, surgical margins, PSA (pre-surgery, pre- and post-RT), RT technique, use of ADT, pelvic nodal irradiation (PNI) and toxicity. Follow-up time was calculated from the completion of the RT treatment. Radiological staging was performed using computed tomography and technetium-99 bone scan. Positron-emission tomography (PET) with gallium-labelled prostate specific membrane antigen (PSMA) or magnetic resonance imaging (MRI) was ordered at the discretion of the treating clinician.

The radiation dose and method of delivery varied with time. 3-dimensional conformal radiation therapy (3DCRT) was used exclusively until mid-2011 whilst IMRT/VMAT techniques were used exclusively from 2012 (see Fig. 1). The clinical target volumes were contoured using the consensus guidelines published by the Australian and New Zealand Radiation Oncology Genito-Urinary Group.\textsuperscript{7} Pelvic nodes were included in the treatment field at the discretion of the treating physician, primarily based on adverse histological features.

After RT, patients were evaluated by PSA measurements every 3–6 months for at least 5 years. Primary endpoint was BCR after RT. As per RAVES trial protocol,\textsuperscript{8} BCR was defined by PSA \( > 0.2 \) ng/mL and BCR endpoints were analysed using Kaplan–Meier methods. The influence of prognostic factors on BCR were assessed using the log-rank test and Cox regression analysis. \( P \) values less than 0.05 were considered statistically significant. The secondary endpoint was the assessment of acute and late toxicities graded according to Radiation Therapy Oncology Group (RTOG) criteria.\textsuperscript{9}

\section*{Results}

Patient characteristics are outlined in Table 1. Median follow-up time after RT was 28 months (range 1–79) regardless of RT technique. Patients treated with 3DCRT were followed for a median of 29 months (range 3–79) while those treated with IMRT or VMAT had a shorter median follow-up time of 17 months (range 1–43). Median RT dose was 65 Gy (range 64–72) in 32–38 fractions (median = 33), although a dose of 66 Gy in 33 fraction was used almost exclusively from 2012. The majority of patients had T3 staging (extra-prostatic extension or seminal vesicle invasion) and Gleason 7 disease was the most common histology. Almost 50\% of patients had clear margins at the time of surgery. Mean time to receive RT after RP was 2.64 years. ADT administration was not consistent and was administered in only 28 (22\%) patients. The use of prophylactic PNI was similarly sparse and was delivered in 20 (15\%) patients.

BCR occurred in 32 of the 126 patients (25\%) whose PSA levels have been monitored post-RT. At 24 and 36 months, 85\% and 75\% of patients were BCR-free, respectively. Patients with a pre-RT PSA above 0.2 ng/mL had a higher probability of recurrence than patients with values below 0.2 ng/mL (\( P = 0.03, \) log rank test) (Fig. 2). RT technique, PNI, androgen deprivation therapy, T staging or surgical margin did not significantly impact BCR results using this method.

Similarly, the impact of age, ADT administration, pre-RT PSA, inclusion of pelvis irradiation and RT technique on BCR were assessed using Cox regression. Of these five covariates, some evidence exists at the 10\% level of significance of dependency between BCR and each of pre-
RT PSA ($P = 0.05$) and pelvic irradiation ($P = 0.08$). Specifically for PSA, the risk of biochemical recurrence is estimated to increase by 29% (95% CI: 0–67%) on average for each ng/mL increase in PSA. No systematic effect on BCR of age, administration of ADT, and RT technique is suggested by the data.

60 patients (46%) had varying degree of urinary incontinence between surgery and RT. Three patients required a urethral sling procedure prior to RT. RT toxicity is outlined in Table 2. 60% of patients developed grade 1 or 2 acute GI toxicities and 44% developed grade 1 or 2 acute GU toxicities. 11% and 12% of patients developed Grade 1 or 2 late GI and GU toxicity, respectively. 11% and 12% of patients developed Grade 1 or 2 late GI and GU toxicity, respectively. 11 patients required colonoscopies or sigmoidoscopies to investigate per rectal bleeding, with only one documented need for photocoagulation of rectal telangiectasia. Similarly, only one patient required surgical intervention for late GU toxicity. There is a trend in the relationship between IMRT/VMAT technique and lower late GI toxicity ($P = 0.004$) (Fig. 3), however, in light of the short follow-up (particularly in the patients treated with IMRT/VMAT) these results should be interpreted with caution until a longer follow-up duration is achieved. No such trend is evident for late GU toxicity ($P = 0.72$) and further follow-up is required.

**Discussion**

Approximately one-third of Australians affected by cancer live in regional or rural areas\(^\text{10}\) and those with prostate cancer continue to endure less rates of screening and poorer survival outcomes. This is due to a variety of reasons including lower availability of diagnostic or treatment services, late presentation and diagnosis, lower socioeconomic status, reduced rates of physical activity and a higher proportion of Aboriginal and Torres Strait Islander (ATSI) peoples.\(^\text{11,12}\) The concept of treatment “quality” is also pertinent and has been addressed in the management of head and neck cancer, in which treatment outcomes have been shown to correlate to the volume of cases treated at a particular centre.\(^\text{13}\) Although the management of prostate cancer may not necessarily be as complex as head and neck cancer, regional institutions in Australia are starting to acknowledge the differences in throughput and regularly compare their outcomes to their metropolitan counterparts. ROC Toowoomba delivers approximately 900 courses of radiation treatment annually and offers a full complement of Oncology and Urology services with a fortnightly multidisciplinary meeting. It also has access to advanced imaging modalities including PSMA-PET and multi-parametric MRI (mp MRI).

**Oncologic outcomes**

Current national and international guidelines recommend that high risk patients be offered Adjuvant Radiation Therapy (ART)\(^\text{7,14,15}\) after RP due to the evidence provided by three randomised trials\(^\text{5,16,17}\) and a meta-analysis.\(^\text{18}\) ART is defined as RT commenced prior to 6 months post-RP. These studies show improved biochemical control, reduced local and metastatic failure, improved quality of life (QoL) with SWOG 8,794\(^\text{17}\) even showing improved overall survival. Whether it be
clinician scepticism of benefits or concerns regarding toxicity, the utilisation of ART is lacking, and may be less than 10%.\textsuperscript{19} In this cohort, 16 (12%) patients were treated with ART. This rate is comparable to current national practice, acknowledging the heterogeneous patient population.

The question of ART versus early salvage RT (esRT) upon detectable rising PSA remains to be answered. The available evidence supporting the efficacy of salvage RT is based on retrospective series.\textsuperscript{20,21} Various phase III trials are currently investigating this including the RAVES,\textsuperscript{8} GETUG-17 (NCT00667069) and RADICALS trials (NCT00541047).

Post-operative PSA remains a crucial variable in determining the success of esRT\textsuperscript{22} and current guidelines recommend instituting salvage RT at the first sign of PSA recurrence\textsuperscript{15} and PSA < 0.5 ng/mL. Figure 2 outlines the BCR-free probability for this cohort, divided into pre-RT values above or below 0.2 ng/mL. This reveals a significant difference between the two groups, with separation of Kaplan–Meier curves noticeable after only 24 months. This reinforces the importance of close PSA follow-up in RP patients and the institution of early salvage therapy with PSA < 0.2 ng/mL.

Our 2 and 3 years rates of BCR-free survival are comparable to landmark Phase 3 trials investigating ART (Table 3), acknowledging a shorter follow-up duration, differing progression-free survival (PFS) or BCR definitions and that our cohort includes both adjuvant and salvage patient data.

**Toxicity**

The lack of Grade 3 and 4 acute toxicity in our patient population is very reassuring and emphasises excellent tolerance. Other analyses have identified similarly low rates of RTOG grade 3–4 acute GI and GU toxicities, which estimate rates to be less than 3%.\textsuperscript{24} In terms of late toxicity, analyses of multiple cohorts have found approximately 15% rates of RTOG grade 2 rectal toxicity and <5% rates of grade 3 toxicity.\textsuperscript{25} Rates of grade 2 and 3 urinary toxicity are reported to be slightly less (approximately 10% grade 2 and 5% grade 3) in both multi- and single-institution studies.\textsuperscript{5,26} In our series to date, there has only been 1 reported case of Grade 3 late GU and GI toxicity, respectively. In these instances, a cystoscopy was required for urethral strictures and photocoagulation was necessary for bleeding for rectal telangiectasia. Due to the recent adoption of IMRT/VMAT, the median follow-up of patients treated with these techniques is relatively small at 17 months.

**Table 1. Patient characteristics (n = 130).**

| Characteristic                      | Value                          |
|------------------------------------|--------------------------------|
| Age (years)                        | Median (range) 64 (49,81)       |
| Tumour stage                       | T2 40 (31%), T3 86 (66%), Tx 4 (3%) |
| Nodal status                       | N0 91 (70%), N1 5 (4%), Nx 34 (26%) |
| Gleason score                      | 6 5 (4%), 7 81 (62%), 8 4 (3%), 9 35 (27%), Not reported 5 (4%) |
| Surgical margin                    | Positive 57 (44%), Negative 64 (49%), Equivocal 9 (7%) |
| Pre-RT PSA ≤ 0.2                   | 96 (74%)                        |
| Mean (SD)                          | 0.39 (±0.97)                    |
| RT dose (Gy)                       | Median (range) 65 (64,72)       |
| Time from RP to RT (years)         | Mean (SD) 2.64 (±2.74)          |
| Technique                          | 3DCRT 53 (41%), IMRT or VMAT 77 (59%) |
| ADT                                | Yes 28 (22%), No 102 (78%)      |
| Pelvic nodal irradiation           | Yes 20 (15%), No 110 (85%)      |

RT, radiation therapy; RP, radical prostatectomy; 3D-CRT, 3D-conformal radiation therapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; ADT, androgen deprivation therapy.
Although the use of IMRT/VMAT technique showed a trend towards reducing late GI toxicity, further follow-up is required to confirm true significance. Nonetheless, the low absolute numbers of severe late GI and GU toxicity are encouraging in our contemporary patient population.

Androgen deprivation

There is an increasing interest in the use of neoadjuvant and concurrent ADT in the salvage treatment setting, considering its established role in high risk localised prostate cancer.27 It has recently been shown that the use of 24 months of concurrent and adjuvant bicalutamide in high risk salvage patients improved overall survival and reduced incidence of metastatic disease.28 Even in the era of ultra-sensitive PSA assays, patients salvaged early (PSA < 0.5) and with negative margins seem to benefit from the addition of ADT.29 These results, in addition to the ongoing SPPORT (NCT00567580) and RADICALS (NCT00541047) trials will hopefully clarify the role of ADT in the adjuvant or salvage setting. The use of ADT in our cohort was low (22%) and although there was a trend towards improved BCR, no significant association was found ($P = 0.15$). At our centre, ADT was offered to patients with an adequate performance status, T3 disease (or T2 disease with positive margins) or a high pre-treatment PSA. This is based on RTOG960128 inclusion criteria.

Pelvic nodal irradiation

The routine use of prophylactic PNI in addition to prostate bed treatment in high risk patients with biochemical relapse lacks phase III evidence, which has also translated into low utilisation in our series. Retrospective series,30 risk stratification formulae 31 and the emergence of more sophisticated imaging techniques32 will continue to guide clinicians in selecting suitable patients for elective PNI. 32 The SPPORT trial (NCT00567580) is exploring short-term ADT with or without the addition PNI and RTOG 0924 (NCT01368588) is solely investigating the addition of PNI in unfavourable intermediate or favourable HRPC patients. While waiting for more confirmatory evidence, there seems to be a trend to delivering PNI in the post-prostatectomy setting, particularly utilising advanced imaging modalities to rule out nodal disease prior to RT. A recent survey of 999 international radiation oncologists33 suggested PNI was offered by 74%. There is a similar trend in our own centre since 2015.

Limitations

This study has inherent limitations as a retrospective, single institution chart review. Ideally, a 5 years median follow-up would be more clinically meaningful, considering the natural history of prostate cancer. An update of our data in 5 years’ time would allow the
reporting of more relevant efficacy end points such as prostate-specific cancer survival and overall survival as well as more meaningful comments in regards to late toxicity. Next, small sample size from a single institution carries selection biases. For example, some patients with BCR who have particularly high risk disease characteristics may have been offered ADT alone rather than be referred for RT. Finally, while all effort is used to standardise toxicity scoring at our centre, these outcomes are naturally prone to recall and misclassification bias.

**Conclusion**

At ROC Toowoomba, early RT (PSA < 0.2 ng/mL) was associated with significant improvement in BCR-free survival, supporting the role of early RT intervention. The low utilisation of ART corresponds to current national and international practice. Rates of d toxicity mirror those of large landmark trials and suggest no detriment for patients treated at our RCC. The use of IMRT or VMAT techniques was associated with a trend towards reduced rates of GI toxicity. Due to low patient numbers in the ADT and PNI subgroups, their utilisation has not translated to a significant benefit in BCR. This data contributes to the growing evidence of non-inferior treatment quality delivered in non-metropolitan centres.

**References**

1. Morlacco A, Karnes RJ. High-risk prostate cancer: The role of surgical management. *Crit Rev Oncol Hematol* 2016; **102**: 135–43.
2. Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study. *Lancet* 2016; **388**: 1057–66.
3. Shakespeare TP. Adjuvant radiotherapy after radical prostatectomy: A failure of marketing-based medicine? *J Med Imaging Radiat Oncol* 2016; **60**: 239–43.
4. Chua B, Min M, Wood M, et al. Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: Planning data and acute toxicity outcomes. *J Med Imaging Radiat Oncol* 2013; **57**: 482–9.
5. Wiegel T, Bartkowiak D, Botke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. *Eur Urol* 2014; **66**: 243–50.
6. Toowoomba Statistical Area: Australian Bureau of Statistics; [updated 23/09/2016]. Available from: http://stats.abs.gov.au/itt/r.jsp?RegionSummary&region=317&dataset=ABS_REGIONAL_ASGS&geoconcept=
7. Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. *Radiother Oncol* 2008; **88**: 10–19.
8. Pearse M, Fraser-Browne C, Davis ID, et al. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: Background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. *BJU Int* 2014; **113**(Suppl 2): 7–12.
9. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys* 1995; **31**: 1341–6.
10. Cancer in rural Australia: Fact Sheet 8: National Rural Health Alliance Inc; 2012. Available from: http://ruralhealth.org.au/sites/default/files/publications/fact-sheet-08-cancer-r-rural-australia.pdf.
11. Baade PD, Youlden DR, Coory MD, Gardiner RA, Chambers SK. Urban-rural differences in prostate cancer outcomes in Australia: What has changed? *Med J Aust* 2011; **194**: 293–6.
12. Fox P, Boyce A. Cancer health inequality persists in regional and remote Australia. *Med J Aust* 2014; **201**: 445–6.
13. Wuthrick EJ, Zhang Q, Machtay M, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. *J Clin Oncol* 2015; **33**: 156–64.
14. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. *Eur Urol* 2011; **59**: 61–71.
15. Valicenti RK, Thompson I Jr, Albertsen P, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. *Int J Radiat Oncol Biol Phys* 2013; **86**: 822–8.
16. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). *Lancet* 2005; **366**: 572–8.
17. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. *J Urol* 2009; **181**: 956–62.
18. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. *Cochrane Database Syst Rev* 2011; **12**: Cd007234.
19. Daniels CP, Millar JL, Spelman T, Sengupta S, Evans SM. Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the Prostate Cancer Registry. *J Med Imaging Radiat Oncol* 2016; 60: 247–54.

20. Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: Results of a match-controlled multi-institutional analysis. *Eur Urol* 2012; 62: 472–87.

21. Fossati N, Karnes RJ, Boorjian SA, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: Results from a multi-institutional series. *Eur Urol* 2017; 71: 886–93.

22. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol* 2007; 25: 2035–41.

23. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. *Eur Urol* 2014; 65: 467–79.

24. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. *J Urol* 2013; 190: 441–9.

25. Landoni V, Fiorino C, Cozzarini C, Sanguineti G, Valdagni R, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. *Phys Med* 2016; 32: 521–32.

26. Lee SW, Hwang TK, Hong SH, et al. Outcome of postoperative radiotherapy following radical prostatectomy: A single institutional experience. *Radiat Oncol J* 2014; 32: 138–46.

27. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. *Cochrane Database Syst Rev* 2006; 4: CD006019.

28. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. *N Engl J Med* 2017; 376: 417–28.

29. Parekh A, Chen MH, Graham P, et al. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. *Clin Genitourin Cancer* 2015; 13: e1–6.

30. Moghanaki D, Koontz BF, Karlin JD, et al. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. *Cancer* 2013; 119: 52–60.

31. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Clin Oncol* 2005; 23: 7005–12.

32. Rischke HC, Eiberger AK, Volegova-Neher N, et al. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases. *Adv Med Sci* 2016; 61: 212–18.

33. Moghanaki D, Urdaneta AI, Karlin JD, Koontz BF, Anscher MS. Management of postprostatectomy biochemical relapse with salvage radiotherapy: Results of an international survey. *Am J Clin Oncol* 2016; 39: 64–8.

34. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. *J Clin Oncol* 2007; 25: 2225–9.